# Keymed Biosciences (KYM Biosciences)

Source: https://onco.cc/companies/keymed/  
OnCo record `keymed` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chinese biotech whose joint venture KYM Biosciences created the Claudin 18.2 ADC CMG901, licensed to AstraZeneca in 2023.

## Summary

Keymed Biosciences, based in Chengdu and listed in Hong Kong as 2162.HK, is the Chinese biotechnology company whose joint venture KYM Biosciences created CMG901, a Claudin 18.2 antibody-drug conjugate licensed to AstraZeneca in 2023. KYM Biosciences is owned seventy percent by Keymed and thirty percent by Lepu Biopharma, and it licensed CMG901, now sonesitatug vedotin or AZD0901, to AstraZeneca in February 2023 for 63 million dollars upfront and up to 1.1 billion dollars in milestones; AstraZeneca runs the phase 3 CLARITY-Gastric01 programme. OnCo links it to gastric and gastro-oesophageal junction cancer, to Claudin 18.2 as a target, to the ADC technology and to the sonesitatug vedotin drug record. Whether an ADC beats a naked antibody against the same target is the open question. Sonesitatug vedotin has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Chengdu
- Type: biotech
- Website: https://www.keymedbio.com
- Ticker: 2162.HK

## Sources

- Licence announcement: https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate.html

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- drugs: [Sonesitatug vedotin](https://onco.cc/drugs/cmg901/)
- trials: [A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct05299424/), [A Study of CM350 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05263960/), [Study of CM518D1 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07019779/)

---
JSON: https://onco.cc/api/v1/entities/keymed.json